BAY1834845 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Inflammatory Disease
Conditions
Pelvic Inflammatory Disease
Trial Timeline
Feb 13, 2017 → Mar 29, 2018
NCT ID
NCT03054402About BAY1834845 + Placebo
BAY1834845 + Placebo is a phase 1 stage product being developed by Bayer for Pelvic Inflammatory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03054402. Target conditions include Pelvic Inflammatory Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03054402 | Phase 1 | Completed |
Competing Products
11 competing products in Pelvic Inflammatory Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 85 |
| BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 22 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 51 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 84 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 74 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |